



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 January 2022
EMA/HMPC/493697/2021
Committee on Herbal Medicinal Products (HMPC)

Addendum to Assessment report on *Marrubium vulgare* L., herba

| | |
|---------------|-----------------------------|
| Rapporteur(s) | J. Wiesner |
| Assessor(s) | F. Deget |
| Peer-reviewer | M. Příhodová / M. Heroutová |

| | |
|--|------------------------------------|
| HMPC decision on review of monograph <i>Marrubium vulgare</i> L., herba adopted on 09 July 2013 | 13 January 2021 |
| Call for scientific data (start and end date) | From 01 April 2021 to 30 June 2021 |
| Adoption by Committee on Herbal Medicinal Products (HMPC) | 26 January 2022 |

Review of new data on *Marrubium vulgare* L., herba

Periodic review (from 2012 to 2021)

Scientific data (e.g. non-clinical and clinical safety data, clinical efficacy data)

☒ Pharmacovigilance data (e.g. data from EudraVigilance, VigiBase, national databases)

The EudraVigilance database was searched on 14/07/2021 using the keywords "*Marrubium vulgare*", and "Horehound liquid extract"

☒ Scientific/Medical/Toxicological databases

Base; Embase; Pubmed; Biomedical Reference Collection; DynaMed (result of 03/08/2021):
key words "*Marrubium vulgare*"

☐ Other

Regulatory practice

☒ Old market overview in AR (i.e. products fulfilling 30/15 years on the market)

☒ New market overview (including pharmacovigilance actions taken in member states)

☐ Referral

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



☒ Ph. Eur. monograph

☐ Other

Consistency (e.g. scientific decisions taken by HMPC)

☒ Public statements or other decisions taken by HMPC

☒ Consistency with other monographs within the therapeutic area

☒ Other

Availability of new information (i.e. likely to lead to a relevant change of the monograph)

| <i>Scientific data</i> | Yes | No |
|--|--------------------------|-------------------------------------|
| New non-clinical safety data likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New clinical safety data likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New data introducing a possibility of a new list entry | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New clinical data regarding the paediatric population or the use during pregnancy and lactation likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New clinical studies introducing a possibility for new WEU indication/preparation | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Other scientific data likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| <i>Regulatory practice</i> | Yes | No |
| New herbal substances/preparations with 30/15 years of TU | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New herbal substances/preparations with 10 years of WEU | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Other regulatory practices likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Referrals likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| New / Updated Ph. Eur. monograph likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| <i>Consistency</i> | Yes | No |
| New or revised public statements or other HMPC decisions likely to lead to a relevant change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Relevant inconsistencies with other monographs within the therapeutic area that require a change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Other relevant inconsistencies that require a change of the monograph | <input type="checkbox"/> | <input checked="" type="checkbox"/> |

Summary and conclusions on the review

During the review, 46 new references not yet available during the first/previous assessment were identified. Filter used were "English language" and "peer-reviewed journals".

No references were provided by Interested Parties during the Call for data.

Two references were considered to be relevant for the assessment.

No references justify a revision of the monograph.

The Ph. Eur. monograph on *Marrubii herba* (10.0/1835) was meanwhile updated. Therefore the footnote 2 in the HMPC monograph "ref.: 01/2008:1835 corrected 6.0" is not valid anymore.

There are no new data/findings of relevance for the content of the monograph.

Reference to the updated pharmacopoeial monograph will be introduced in the HMPC monograph when it is revised.

Scientific data

In two review articles from Lodhi *et al.* (2017) and Aćimović *et al.* (2020), the traditional medicinal use and many pharmacological studies were summarised and discussed.

It was reported that *Marrubium vulgare* is widely used as an herbal remedy for chronic coughs and colds. Furthermore, it is reported to be used in various disorders related to skin, liver, gastric, heart, and immune system.

According to numerous studies, *Marrubium vulgare* acts as an antioxidant agent and due to this, it could potentially be useful in treatments of cancer, diabetes mellitus, and liver diseases. In addition, its antinociceptive, anti-inflammatory, wound-healing, antihypertensive, hypolipidemic, antidiabetic, gastroprotective, antihepatotoxic, antispasmodic, sedative, antimicrobial and antiviral potential are discussed.

However, it was summarised that further scientific studies are needed to explore clinical efficacy and toxicity.

Assessor's comment:

No revision is considered required because in both review articles the pharmacological properties discussed are based on pre-clinical studies (mainly in-vitro) which would not lead to a change in the monograph. No clinical studies are mentioned in the articles cited.

Eudravigilance data:

In EudraVigilance database for the period up to July 2021 there was one spontaneous report (from 2020) of suspected adverse drug reaction associated with *M. vulgare*. A woman (46 years old) took Pancreatin, a calcium antagonist and due to ear pain *M. vulgare*. Five days after starting therapy with *M. vulgare* she developed haematoma. The patient recovered from haematoma although continuing taking *M. vulgare*.

Assessor's comment:

There are no new safety concerns from the case report in the Eudravigilance database up to July 2021.

References

a) References relevant for the assessment:

Aćimović M, Jeremić K, Salaj N, GavarićN, Kiprovski B, Sikora V, *et al.* *Marrubium vulgare* L.: A phytochemical and pharmacological overview. *Molecules* 2020, 25:2898, in press, doi 10.3390/molecules25122898

European Pharmacopoeia 10th ed. *Marrubii herba*. Council of Europe 01/2019:1835

Lodhi S, Vadnere G, Sharma V, Md. Usman R. *Marrubium vulgare* L.: A review on phytochemical and pharmacological aspects. *J Intercult Ethnopharmacol* 2017, 6(4):429-452

b) References that justify the need for the revision of the monograph:

None

Rapporteur's proposal on revision

- ☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
- ☒ No revision needed, i.e. no new data/findings of relevance for the content of the monograph

HMPC decision on revision

- ☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
- ☒ No revision needed, i.e. no new data/findings of relevance for the content of the monograph

The HMPC agreed not to revise the monograph, assessment report and list of references on *Marrubium vulgare* L., herba, by consensus.